Behrens et al., 2001 - Google Patents

DONOR-DERIVED SOLUBLE MHC ANTIGENS PLUS LOW-DOSE CYCLOSPORINE INDUCE TRANSPLANTATION UNRESPONSIVENESS INDEPENDENT OF THE …

Behrens et al., 2001

View PDF
Document ID
8405912972508942105
Author
Behrens D
Lange K
Fried A
Yoo-Ott K
Richter K
Fändrich F
Krönke M
Zavazava N
Publication year
Publication venue
Transplantation

External Links

Snippet

Background. In vitro, soluble MHC (sMHC) antigens modulate and induce apoptosis in alloreactive and antigen-specific T cells, demonstrating their potency to regulate T cell- mediated immune responses. However, their efficacy to regulate immunological responses …
Continue reading at www.academia.edu (PDF) (other versions)

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70532—B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans

Similar Documents

Publication Publication Date Title
Le Rond et al. Evidence to support the role of HLA-G5 in allograft acceptance through induction of immunosuppressive/regulatory T cells
Chai et al. Regulatory T cells, derived from naive CD4+ CD25− T cells by in vitro Foxp3 gene transfer, can induce transplantation tolerance
Rossini et al. Induction of immunologic tolerance for transplantation
Guillonneau et al. CD40Ig treatment results in allograft acceptance mediated by CD8+ CD45RC low T cells, IFN-γ, and indoleamine 2, 3-dioxygenase
Ortler et al. B7‐H1 restricts neuroantigen‐specific T cell responses and confines inflammatory CNS damage: Implications for the lesion pathogenesis of multiple sclerosis
Green et al. Neonatal tumor necrosis factor α promotes diabetes in nonobese diabetic mice by CD154-independent antigen presentation to CD8+ T cells
Bohana‐Kashtan et al. Fas ligand as a tool for immunosuppression and generation of immune tolerance
JP2011144205A (en) Immunosuppression by blocking t-cell co-stimulation signal 2 (b7/cd28 interaction)
Ljunggren et al. MHC class I expression and CD8+ T cell development in TAP1/β2-microglobulin double mutant mice
Manning et al. Antigen recognition and allogeneic tumor rejection in CD8+ TCR transgenic/RAG (-/-) mice.
Simon et al. Carbon monoxide‐treated dendritic cells decrease β1‐integrin induction on CD8+ T cells and protect from type 1 diabetes
Zavazava et al. Alloreactivity and apoptosis in graft rejection and transplantation tolerance
Behrens et al. DONOR-DERIVED SOLUBLE MHC ANTIGENS PLUS LOW-DOSE CYCLOSPORINE INDUCE TRANSPLANTATION UNRESPONSIVENESS INDEPENDENT OF THE THYMUS BY DOWN-REGULATING T CELL-MEDIATED ALLORESPONSES IN A RAT TRANSPLANTATION MODEL1
Barbera Betancourt et al. T cell-mediated chronic inflammatory diseases are candidates for therapeutic tolerance induction with heat shock proteins
WO2006033811A2 (en) Ilt3 polypeptides and uses thereof
Reddy et al. THE EFFECT OF CD28/B7 BLOCKADE ON ALLOREACTIVE T AND B CELLS AFTER LIVER CELL TRANSPLANTATION 1
Honey et al. DOMINANT TOLERANCE AND LINKED SUPPRESSION INDUCED BY THERAPEUTIC ANTIBODIES DO NOT DEPEND ON FAS-FASL INTERACTIONS1
Favre‐Felix et al. Flt3 ligand lessens the growth of tumors obtained after colon cancer cell injection in rats but does not restore tumor‐suppressed dendritic cell function
Geissler et al. Effective use of donor MHC class I gene therapy in organ transplantation: prevention of antibody-mediated hyperacute heart allograft rejection in highly sensitized rat recipients
AU776618B2 (en) Improvement of tolerance to a xenograft
WO2016131911A1 (en) Methods for the treatment and diagnosis of type 1 diabetes
Brady et al. Additive Efficacy of CTLA4Ig and OX40Ig Secreted by Genetically Modified Grafts1
Weng et al. Peptide-dependent inhibition of alloreactive T-cell response by soluble divalent HLA-A2/IgG molecule in vitro
Ragheb Exploration of OX-2 function in tolerance induction and graft acceptance using an anti-mouse OX-2 monoclonal antibody
Dao et al. Involvement of CD1 in peripheral deletion of T lymphocytes is independent of NK T cells